Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal how fear of movement changes pain response

NCT ID NCT07688525

Knowledge-focused Sponsor: Université de Sherbrooke Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates how a person's beliefs about pain, such as fear of movement (kinesiophobia), influence brain activity during pain. Healthy adults will have a capsaicin cream applied to their forearm to cause temporary, moderate pain while researchers measure brain signals using non-invasive magnetic stimulation. The goal is to see if people with higher fear of movement show different brain responses to pain, which could help explain why pain affects people differently.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical capsaicin cream (1%)
What this could lead to
If it works, this could help explain why people respond differently to pain and point toward personalized approaches for pain management.
What could go wrong
This is a small, early-stage study in healthy volunteers using temporary pain, so results may not apply to people with chronic pain or other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 35 years, inclusive * Healthy * Able to understand the study information and experimental procedures * Able to provide informed consent Exclusion Criteria: * History of psychiatric disorders (including intellectual disability or severe cognitive, behavioral, or affective impairment) that could interfere with understanding the study or providing informed consent. * History of neurological disorders, including epilepsy, stroke, brain or spinal cord surgery, or any neurological disease affecting motor or sensory function. Inability to provide informed consent (e.g., dementia, significant hearing impairment, insufficient language proficiency). * Any pain condition within the past 3 months, regardless of origin. * Recent musculoskeletal injury or surgery within the past 3 months. * Contraindications to transcranial magnetic stimulation (TMS), including a history of epilepsy or the presence of intracranial metallic objects, cochlear implants, or other non-removable metallic implants in or near the head. * Use of analgesic or psychotropic medications. * Individuals under legal guardianship or curatorship. * Pregnant or breastfeeding women. * Presence of a cardiac pacemaker or other implanted electronic medical device. * Known allergy or previous skin reaction to capsaicin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Experimental pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kinesiophobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Experimental pain Kinesiophobia (fear of movement)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Université de Sherbrooke - Campus de la santé

    Sherbrooke, Quebec, J1H 5H3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.